Financials

News Ideas Technicals

323990 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to VAXCELL-BIO THERAPEUTICS operating, investing, and financing activities

323990 free cash flow for Q1 24 is -4.3 B KRW. For 2023, 323990 free cash flow was -9.59 B KRW and operating cash flow was -9.42 B KRW.

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: KRW

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

TTM

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—